FindTrial
Sign In

Can a Point of Care Urine Tenofovir Assay enhance Adherence to Anti-retroviral Therapy in People Living with HIV ?

Utility, Feasibility & Acceptability of a Point of Care Urine Tenofovir Assay to Monitor Treatment & Enhance Adherence to Anti-retroviral Therapy in People Living with HIV

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/07/055027
Enrollment
60
Registered
2023-07-10
Start date
Unknown
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B20- Human immunodeficiency virus [HIV]disease

Interventions

Intervention1: UTRA test: Enhanced Adherence support package, which is informed by feedback from the UTRA (Urine tenofovir rapid assay) Duration: 3 months Control Intervention1: Standard of Care: For

Sponsors

Fogarty International Centre, NIH
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age > 18 years 2. Viral load >1000 3. PLHIV receiving/restarting a tenofovir-based ART regimen 4. Current ART regimen includes at least one drug with a high genetic barrier to resistance e.g. dolutegravir, protease inhibitors

Exclusion criteria

Exclusion criteria: 1. Not willing or able to provide informed consent in any of the languages provided 2. Any other clinical condition that in the opinion of an investigator puts the patient at increased risk if participating in the study.

Design outcomes

Primary

MeasureTime frame
Virological SuppressionTimepoint: 3 months—

Secondary

MeasureTime frame
Not applicableTimepoint: Not applicable—

Countries

India

Contacts

Public ContactSavitha Anne Sebastian

St Johns Medical College

savithaseb@gmail.com9663780301

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026